Table 1.
Previous cases of irAE IgA vasculitis and the present case.
| No. | Author | Sex | Age | Cancer | Regimen | Time to onset | Affected organ | Treatment | Outcome | Readministration |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Belkaid (4) | M | 70 | Melanoma | Nivolumab + Ipilimumab |
7 months | Skin, gastrointestinal, joint, and renal | Discontinuation of ICI and GC | Remission | – |
| 2 | Mamlouk (5) | F | 50s | Melanoma | Nivolumab + Ipilimumab |
5 weeks | Skin, renal | Discontinuation of ICI, GC, rituximab, plasmapheresis, and hemodialysis | Chronic renal failure | – |
| 3 | Asemota (6) | M | 60 | HCC | Nivolumab | 9 months | Skin, renal | Discontinuation of ICI and GC | Death (after 18 days) |
– |
| 4 | Nagaoka (7) | F | 50 | RCC | Nivolumab | 21 months | Skin, gastrointestinal, joint, and renal | Discontinuation of ICI and GC | Remission | + (late line) |
| 5 | Casafont-Sole (8) | M | 64 | SCC | Durvalumab | 6 months | Skin, renal | Discontinuation of ICI and GC | Remission | – |
| 6 | Kawataki (9) | M | 78 | SCC | Durvalumab | 18 months | Skin, gastrointestinal, and renal | Discontinuation of ICI and GC | Remission | – |
| 7 | Present case | M | 73 | SCC | CBDCA + nab-PTX + Pembrolizumab |
3 months | Skin, gastrointestinal, joint, and renal | Discontinuation of ICI and GC | Remission | – |
F, female; M, male; HCC, hepatocellular carcinoma; RCC, renal cell carcinoma; SCC, squamous cell carcinoma; CBDCA, carboplatin; nab-PTX, nab-paclitaxel; ICI, immune checkpoint inhibitor; GC, glucocorticoid.